MA5-12675

antibody from Invitrogen Antibodies

Targeting: ERBB3 HER3, LCCS2

Provider product page for MA5-12675

Western blot

Other assay

Antibody data

Antibody Data
Antigen structure
References [27]
Comments [0]
Validations
Western blot [2]
Other assay [2]

Submit

Product number: MA5-12675 - Provider product page
Provider: Invitrogen Antibodies
Product name: ErbB3 Monoclonal Antibody (2F12)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: MA5-12675 targets HER-3 in WB applications and shows reactivity with Bovine, Human, mouse, and Rat samples.
Antibody clone number: 2F12
Concentration: 0.2 mg/mL

ERBB3 protein structure - MA5-12675 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Activation of ERBB2 and ERBB3 in BGJ398 RS cells (A) A phospho-RTK array reveals that BGJ398 RS cells have increased phosphorylation of ERBB2 and ERBB3 in the presence of BGJ398. The cell lysates were hybridized to a phospho-RTK membrane, on which each RTK is spotted in duplicate. Hybridization signals at the corners serve as controls. (B) Immunoblot analysis of protein phosphorylation in extracts from parental cells that were treated for the indicated time points with 1muM BGJ398. (C) ERBB2 and ERBB3 dimerization measured by co-immunoprecipitation. The parental cells were treated with 1muM BGJ398 for 24h and prior to lysis. The experiments were performed at least twice.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 BGJ398 RS cell lines are selectively sensitive to tyrosine kinase inhibitors and to shRNA-mediated depletion of ERBB2 or ERBB3 A) BGJ398 RS cells are sensitive to the ERBB family inhibitor. Parental and BGJ398 RS cells were exposed to BGJ398 or AZD8931 alone or in combination, and cell proliferation was measured 4 days after treatment using Cell-Titer-GLO. (B) Immunoblot analysis of protein phosphorylation in extracts from parental and BGJ398 RS cells that were treated for indicated time point with 1muM BGJ398, 1muM AZD8931 or a combination of both drugs. (C) Upper: Immunoblots demonstrate down-regulation of ERBB2 by the specific shRNA. A lacZ control or ERBB2 specific shRNAs were introduced into parental or BGJ398 RS cells. Cells underwent puromycin selection and extracts were immunoblotted with the indicated antibodies. Lower: BGJ398 RS cells are sensitive to knock-down of ERBB2 expression. The number of cells were counted 72 hours after seeding, and the viability of knockdown samples (in triplicate) is presented relative to LacZ control sample. (D) Knockdown of ERBB2 also sensitizes the BGJ398 RS cells to AZD8931. Parental and BGJ398 RS cells were infected with indicated shRNA and the proliferation is shown for indicated cells treated for 96 hours with 1muM BGJ398, 1muM AZD8931 or a combination of both drugs. Proliferation is shown relative to untreated cells at the same time point. The experiments were repeated twice. *, P